Cover Image

Serum Endothelin-1 as biomarker in oral cancer - a case control study

Sumaiya Irfan*, Nishi Tandon, A.N.Srivastava, Richa Sharma, Vijay Kumar


Worldwide, cancers of the oral cavity and pharynx are the 6th most common type & it is a major problem in the Indian subcontinent. Endothelin-1 (ET-1) is a potent vasoconstrictor involved not only in vascular biology but also in carcinogenesis. Serum Endothelin-1 level have been studied in various human cancers like colon & breast. To evaluate significance of serum Endothelin in oral cancer we undertook a case control study. A total of 48 subjects 24 controls and 24 oral cancers were enrolled for the study. Serum Endothelin-1 levels were evaluated by ELISA. The results showed that there was significant difference in serum Endothelin-1 levels in oral cancer and control. Therefore we conclude that serum Endothelin -1 has a potential role as a serum marker for oral cancer progression.


Oral Squamous cell carcinoma; Endothelin -1; Biomarker

Full Text:



Elango JK, Gangadharan P, Sumithra S, Kuriakose MA. Trends of head and neck cancers in urban and rural India, Asian Pacific Journal of Cancer Prevention 7.1 (2006): 108–112.

Sankaranarayanan R, Ramadas K, Thomas G, et al., Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial. The Lancet 9475(2005): 1927–1933.

Shenoi R, Devrukhkar V; Chaudhuri, Sharma BK, Sapre SB, Chikhale A. Demographic and clinical profile of oral squamous cell carcinoma patients: a retrospective study. Indian J Cancer 49.1( 2012): 21-6.

Bishop JM. Molecular themes in oncogenesis. Cell 64(1991):235–48.

Vokes EE et al., Head & neck cancer. N Eng J Med. 324(1993):184.

Forastiere A etal: Head and neck cancer. N Eng J Med. (2001):1890.

Hickey KA, Rubanyi G, Paul RJ, Highsmith RF. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am J Phisiol 248 (1985):C550–6.

Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al., . A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332 (1988):411–5.

Levin ER. Endothelins. N Eng J Med 333(1995):356–63.

Joel Nelson, Anna Bagnato, Bruno Battistini, Perry Nisen. The endothelin-1 axis: Emerging role in cancer. Nature Reviews Cancer3 (2003): 110-116 .

Bagnato A, Tecce R, DiCastro V, Catt K: Activation of mitogenic signaling by endothelin-1 1 in ovarian carcinoma cells. Cancer Res57 (1997): 1306-1311.

Pristivishalil G, Nelson JB. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate44 (2000): 77-87.

Masaki T. The endothelin-1 family: An overview. J. Cardiovasc. Pharmacol 35(2000): S3-S5.

Motte S, Mcentee K, Naeije R. Endothelin receptor antagonists. Pharmacol Ther 110 (2006):386–414.

Bhalla A, Haque S, Taylor I, Winslet M, Loizidou M. Endothelin receptor antagonism and cancer. Eur J Clin Invest39.S2 (2009):74–7.

Shah R. Endothelins in health and disease. Eur J Intern Med18.4 (2007):272–2.

Khimji AK, Rockey DC. Endothelin – biology and disease. Cell Signal 22.11 (2010):1615.

Mangahas CR, dela Cruz GV, Friedman-Jimenez G, Jamal S. Endothelin-1 induces CXCL1 and CXCL8 secretion in human melanoma cells. J Invest Dermatol 125.2 (2005):307–11.

Mangahas CR, dela Cruz GV, Schneider RJ, Jamal S. Endothelin- 1 upregulates MCAM in melanocytes. J Invest Dermatol 123.6(2004):1135–9.

Salani D, Rosano L, Di Castro V, Spinella F, Venuti A, Padley RJ, et al., . ABT-627, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma growth in vitro. Clin Sci 103.48S (2002);:318S–21S.

Rosano L, Salani D, Di Castro V, Spinella F, Natali PG, Bagnato A. Endothelin-1 promotes proteolytic activity of ovarian carcinoma. Clin Sci 103.48S (2002):306S–9S.

Rosano L, Varmi M, Salani D, Di Castro V, Spinella F, Natali PG, et al., . Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res66.22 (2001): 8340–6.

Hoffmann RR, Yurgel LS, Campos MM. Evaluation of salivary endothelin-1 levels in oral squamous cell carcinoma and oral leukoplakia. Regul Pept. 166.1-3 (2011):55–58.

Pickering V, Jordan RC, Schmidt BL. Elevated salivary endothelin levels in oral cancer patients–a pilot study. Oral Oncol43.1( 2007): 37–41.

Cheng YS, Rees T, Jordan L, Oxford L, O'Brien J, Chen HS, Wong D. Salivary endothelin-1 potential for detecting oral cancer in patients with oral lichen planus or oral cancer in remission. Oral Oncol47.12 (2011):1122–6.

Hussein NA, Anwar MM, Elkerm Y, Abozaid NA, Rashad MM Evaluation of serum big endothelin-1 for the diagnosis and prediction of disease recurrence in breast cancer patients. J Cancer Res Ther 1 (2013):178–185.

Asham E. Increased endothelin-1-1 in colorectal cancer and reduction of tumour growth by ETA receptor antagonism. Br J Cancer.85 (2001): 1759-1763.

Peeters CF, Thomas CM, Sweep FC, Span PN, Wobbes T, Ruers TM. Elevated serum endothelin-1-1 levels in patients with colorectal cancer, relevance for prognosis. Int J Biol Markers15.4 (2000): 28- 93.

Iman A. Abdel-Gawad, M.D., Hala M.R. Hassanein, M.D., Nahla A. Bahgat, M.D.,Mona A. Abdel Sattar, M.D.,Azza H. El-Sissy, M.D., Maha A. Altaweel, M.D.AndAmany M. Helal, M.D. Study of Endothelin-1 and Vascular Endothelial Growth Factor in Patients with Cancer Colon. Journal of the Egyptian Nat. Cancer Inst20 (2008): 216-223.

Arun C, Swift B, Porter KE, West KP, London NJ, Hemingway DM. The role of big endothelin-1-1 in colorectal cancer. Int J Biol Markers17.4 (2002): 268-74.

Chalmers GW, Thomson L, Macleod KJ, McGinn BG, McSharry C, Patel KR, Thomson NC. Endothelin-1 levels in induced sputum samples from asthmatic and normal subjects. Thorax 52 (1997):625-627

Bovenzi M, D’Agostin F, Rui F, Ambrosi L, Zefferino R. Salivary endothelin and vascular disorders in vibration-exposed workers. Scand J Work Environ Health 34.2(2008):133–141.

Shuji Awano, Louise A. Dawson, Alison R. Hunter, Anthony J. Turner and Badar A. Usmani. Endothelin system in oral squamous carcinoma cells: Specific siRNA targeting of ECE-1 blocks cell proliferation Int. J. Cancer 118(2006): 1645–1652.



  • There are currently no refbacks.

Copyright (c) 2015 International Journal of Bioassays

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

International Journal of Bioassays is a member of the Publishers International Linking Association, Inc. (PILA), CROSSREF and CROSSMARK (USA). Digital Object Identifier (DOI) will be assigned to all its published content.